BCL2 and lung carcinoma: The non-peptidic small molecule BDA-366 has previously been described to function as a Bcl-2 antagonist by targeting Bcl-2’s BH4 domain23, thereby inducing apoptosis in lung cancer and multiple myeloma cells24.